Background Several tyrosine kinase inhibitors (TKIs) are approved for the treatment of chronic myeloid leukemia (CML). Decision-analytic modeling can help to extrapolate data from short-term clinical trials and also consider quality of life when evaluating different treatment strategies. Objective Our goal was to describe and analyze the structural and methodological approaches of published decision-analytic models for various treatment strategies in CML and to derive recommendations for the development of future CML models.
Results We identified 18 different decision-analytic modeling studies. Of these, 17 included economic evaluations. Modeling approaches included decision trees, Markov cohort models, state-transition models with individual (Monte Carlo) simulations, and mathematical equations. Analytic time horizons ranged from 2 years to a lifetime. Treatment strategies compared included bone marrow or stem cell transplantation, conventional chemotherapy, interferon-a, and TKIs. Only one model evaluated a second-generation TKI. Most models did not report a model validation. All models conducted deterministic sensitivity analyses and four reported a probabilistic sensitivity analysis. Limitations Articles that were not published in English or German were not included in this review. Our literature search was restricted to published full-text articles in certain databases. Therefore, publications that met our inclusion criteria but were published in different databases, different languages, or as abstracts only may have been missed. Conclusions While several well-designed models of CML treatment strategies exist, there remains a need for the assessment of the long-term efficacy and cost effectiveness of novel treatment options such as second-generation TKIs. Additionally, these models should be validated using independent data.
Key Points for Decision Maker
• We provide a comprehensive overview and summary of existing decision-analytic models for the treatment of chronic myeloid leukemia (CML).
• The results are valuable for CML decision modelers.
Future modeling projects benefit from insight in already existing CML models and former modeling experiences (e.g., choosing an appropriate time horizon, selecting health states to model the disease as well as the modeling approach).
• Clinicians are supported in finding an appropriate model for their clinical guideline development (e.g., decisions on performing stem cell transplantation).
Using modeling results to support informed evidencebased clinical decision making will improve the care of patients.
• Health policy makers can use the results to identify appropriate models and compare modeling results from different settings to support their own decision making.
Introduction
Chronic myeloid leukemia (CML) is a fatal, hematologic cancer disease. The course of the disease is typically characterized by three distinct phases: chronic phase (CP), accelerated phase (AP), and blast crisis (BC) [1] . The introduction of molecular-targeted treatment has revolutionized therapeutic management of CML and turned the disease into a more chronic condition [2] . According to current treatment recommendations from the European Leukemia Net (ELN), imatinib, nilotinib, and dasatinib are considered standard first-line treatments. Recommended second-line treatments include a, second-or third-generation tyrosine-kinase-inhibitor (TKI) such as dasatinib, nilotinib, bosutinib, or ponatinib. In the event of drug failure, stem cell transplantation (SCT) is recommended for eligible patients in AP or BC. However, because of chronic graft-versus-host disease, allogeneic SCT is associated with considerable mortality and morbidity [3] . Quality-of-life (QoL) measurements and long-term efficacy is particularly important in the early phase of a pharmaceutical's life cycle when (a) long-term data are lacking, (b) several sequential applications of treatment are possible, and (c) head-to-head trials are unavailable [4, 5] . Clinical trials often suffer from short time horizons, assessment of few treatment alternatives, and scarce evaluation of treatment impact on QoL.
Decision-analytic modeling has overcome these limitations [5] . Mathematical decision models can be used to link diagnostic and prognostic information with short-term clinical outcomes from clinical trials and other data sources, extrapolate the data, and therefore analyze long-term consequences of different treatment strategies. Furthermore, adjusting results using patient preference data and incorporating costs can help to guide clinicians and healthcare policy officials to make informed decisions in identifying the optimal strategy for patients or to maximize the health benefits of certain populations [6] [7] [8] [9] [10] .
The chronic nature of CML warrants the use of models that can account for both the initial response to treatment and translate these responses to long-term outcomes. Achieving balance between a model that accurately reflects the complexity of this disease and a model that is simplistic and straightforward enough for rational decision makers to understand remains a challenge and will be even more challenging with the introduction of personalized healthcare concepts.
At present, several mathematical decision-analytic models of CML treatment strategies have been published. However, to our knowledge, a comprehensive systematic review has not been published. Therefore, the aim of this study is to provide an overview of structural and methodological approaches used in CML decision modeling for clinicians, health policy makers, researchers, and decision analysts. This critical review is intended to support the development of future CML models and aid in the selection of an optimal approach for answering specific research, clinical, and health policy questions. However, our goal was not to perform quality assessment or benchmarking of published models.
Material and Methods

Systematic Literature Search
We performed a systematic literature search in electronic databases (MEDLINE/PreMEDLINE, EconLit, EM-BASE, NHS EED, and Tufts CEA Registry) using appropriate keywords and MeSH terms covering the disease and mathematical or decision-analytic modeling (see Online Resource 1). The search was restricted to the English and German languages, published full-text articles, and human subjects. No restrictions on publication date were applied. The most recent search was carried out in August 2013.
All decision-analytic models and other types of mathematical healthcare models [e.g., area under the curve (AUC) models, decision trees, Markov cohort models, state-transition microsimulations, discrete event simulations (DES)] were included. The ''ISPOR task force on Good Research Practices-Modeling Studies'' defines a healthcare evaluation model as ''an analytical methodology that accounts for events over time and across populations, […] whose purpose is to estimate the effects of an intervention on valued health consequences and costs'' [11] . We excluded all studies in which the treatment of CML was not the primary focus. Furthermore, studies consisting only of economic evaluations as part of a clinical trial, studies that did not describe a model, only described parts of a model, or employed a model only for illustration or tutorial purposes were also excluded. Other exclusions include studies that were published in any language other than English or German, did not have a full-text version available, or were animal/in vitro studies. We specifically focused on the methodological aspects rather than on study results.
Data Extraction and Model Assessment
We adapted a standardized assessment form, which was used previously in a decision-analytic model review [12] , to extract data from the included studies. This assessment was based on guidelines and recommendations for decision modeling and cost-effectiveness analysis [9, 13, 14] . Furthermore, we considered key attributes that define good healthcare decision modeling practices such as target population, analytic framework (e.g., time horizon, analytical approach, perspective), data sources, model validation, results, and conclusions as stated by the Task Force on Good Research Practices-Modeling Studies [15] .
All data were independently extracted and assessed by two of the authors (UR, RS) [16] using the standardized assessment form. If they did not agree and could not reach a consensus, the issue was reviewed by a third person (BJ) and discussed within the authorship group. If clinical questions arose, CML experts (DW and GG) were consulted. The agreed-upon version of the extracted data was summarized in evidence tables to systematically demonstrate the methodological approaches and main results of each study. In the tables, the models were grouped by treatment approach as follows: (1) pre-imatinib era (2) imatinib era (3) second-generation TKIs and (4) bone marrow transplantation (BMT)/peripheral SCT. The reason for this classification is that the introduction of targeted therapies, first imatinib, and later second-generation TKIs, revolutionized the treatment of CML, which has turned the disease into a more chronic condition. The transplantation group was added because of the particularities of the associated health states and the course of the disease when transplantation is evaluated as a comparator.
Additionally, we provided a short description and evaluation of specific modeling aspects (e.g., modeling approach, time horizon, uncertainty analysis, model validation) taking into account the ISPOR SMDM Joint Task Force on Good Research Practices-Modeling Studies [15] .
Results
Systematic Literature Search
A systematic search across all databases (MEDLINE/Pre-MEDLINE, EconLit, EMBASE, NHS EED, and Tuft's CEA Registry) yielded 817 hits. After exclusion of duplicates and two screening steps, 21 articles were included for analysis. Online Resource 1 contains the stated reasons why each of the studies in the full-text screening step was excluded. Among the included articles, one was published twice in two different languages [17, 18] and another two were published as an Health Technology Assessment (HTA) report [19, 20] as well as a journal article [21, 22] . Thus, 18 unique modeling studies were included in the review (Fig. 1 
Treatment Strategies
The models assessed the following treatment strategies: BMT/peripheral SCT [23] [24] [25] [26] [27] , conventional chemotherapy (e.g., hydroxyurea (HU) or busulfan) [17, 19, 24, 25, [27] [28] [29] [30] [31] [32] , interferon-a (IFNa) or IFNa with low-dose cytarabine [17, 19, 22, 24, 25, [27] [28] [29] [30] [33] [34] [35] , imatinib [19, 22, 23, 26, 27, [31] [32] [33] [34] [35] [36] , dasatinib [22, 27, 36, 37] , and nilotinib [22, 27, 36] . The models will be evaluated in the upcoming paragraphs using the guidelines of the ISPOR SMDM Joint Task Force on Good Research Practices-Modeling Studies [15] .
Types of Modeling Approaches and Health States
Twelve studies used a state-transition Markov model as a modeling approach, whereas three of these explicitly used a combination of a decision tree (first 8 or 12 months) and a Markov model. Two studies applied a survival partitioned model (SPM). One study used an AUC estimation for a fitted Gompertz model. In three studies, the approach was not explicitly stated.
The structure of a SPM is similar to state-transition Markov models. The course of disease is also split up into different health states. However, instead of using transition probabilities to determine the transition from one state into another state within each cycle, in SPMs, an AUC method is used [27] .
The basic structures of the models reviewed were relatively similar. The majority employed a state-transition model (n = 12) evaluated as a Markov cohort simulation comprising the main health states of the disease (CP, AP, BC) and response to therapy. This is consistent with the recommendations of the ISPOR-SMDM Modeling Good Research Practices Task Force that state ''if the decision problem can be represented with a manageable number of health states that incorporate all characteristics relevant to the decision problem, including the relevant history, a cohort simulation should be chosen'' [38] .
Liberato et al. was the only study that did not distinguish between AP and BC. They only mentioned BC. This could have lead to an inaccuracy in utilities (AP and BC are often assigned different utility values) as well as costs (as BC is usually more cost intensive).
Some authors separated the CP health state into different levels (e.g., molecular or cytogenetic response) of responders and no-responders to model more closely the underlying biological response to treatment. Guideline recommendations for treatment changes and failure status take into account the level of response of the patients [3, 39] . When treatment and modeling move to a more personalized approach, consideration of response level will be even more important.
The simulation approach was not always sufficiently described. Deterministic cohort simulation was used most often (n = 11); one study included both a Markov cohort analysis and a first-order Monte Carlo microsimulation. All studies except one (n = 17) evaluated cost-effectiveness/ cost-utility ratios for the treatment alternatives.
One of these state-transition models first used a cohort simulation to determine the incremental cost-effectiveness ratio (ICER). In addition, the authors performed a firstorder Monte Carlo simulation to investigate the heterogeneity of outcomes [26] .
The ISPOR-SMDM Modeling Good Research Practices Task Force also recommends modeling initial immediate or short-term events as a decision tree preceding the state-transition model [38] . Three authors [17, 28, 29] explicitly stated that they incorporated a decision tree (first 8 or 12 months) into their model because the literature indicated that the transition probabilities in the first months Tufts CEA Registry Tuft's Cost-effectiveness Registry. * excluded because they did not evaluate a treatment strategy for CML, were purely descriptive studies, or studies using models only as an illustration of CML differ from those in subsequent months. Another approach to account for different transition probabilities was chosen by Pavey et al. [36] in which the authors used an age-dependent Weibull function to consider non-constant transition probabilities from first-line TKI therapy to subsequent health states [36] .
Time Horizon
The 
Uncertainty Analysis
The importance of uncertainty analyses has been underscored by the ISPOR-SMDM joint task force ''the systematic examination and responsible reporting of uncertainty […] are the hallmarks of good modeling practice'' [40] . The goal is to explore the robustness of a model's outcomes when the model's inputs change. Sensitivity analyses also allow questions of generalizability to other settings to be explored [40] . There are two main areas of uncertainty: parameter and modeling-related uncertainty [41] . All models in our review investigated the parameter uncertainty in conducting deterministic sensitivity analyses. Only six models reported a probabilistic sensitivity analysis [19, 34, 35, 37] that specifically examines the imprecision and uncertainty in estimating the parameters themselves [42] .
Modeling uncertainty is related to the structure of a model or the overall process of modeling such as the choice of the health states [43] . For example, structural sensitivity analysis was explicitly reported by Beck et al. [29] . The structure of the model relied on a clinical trial. In the structural sensitivity analysis, the authors investigated the effect of structural deviations from the original trial. For example, not allowing crossover or eliminating the possibility of SCT [29] . This example demonstrates how important assumptions can be varied and how their influence on the decision can be evaluated. Structural sensitivity analyses are also a powerful tool when investigating the transferability to other settings. An example of this would be, in cases when SCT is not available or cross-over not allowed. Another example to evaluate the impact of structural uncertainty can be found in Hoyle et al. [22] . In a sensitivity analysis, they modeled the overall survival differently: ''Given that there is considerable structural uncertainty in the assumed relationship between response rate and overall survival, overall survival was modeled in a completely different way'' [22] . None of the models performed a formal value-of-information analysis, using the model to evaluate further research priorities [40, 44] . 
Quality of Life and Utility Derivation
QALYs are an important outcome of cancer therapy because they account not only for the prolongation of life, but also the quality of that life. As more patients are treated with TKIs and are expected to live longer, the quality of the years gained will play a central role in evaluating therapies. All but two models [26, 30] considered utilities to adjust life-years for QoL. The ISPOR Task Force on Good Research Practice recommends using ''validated health-related quality-oflife instruments with prespecified scoring systems based on ''forced-choice'' methods [standard gamble, time trade-off (TTO)]'' [11] . The majority of the models used clinical expert opinion to derive the utilities [17, 22, 24, 25, 27-29, 31, 32, 36] . Seven studies [19, 22, 27, [33] [34] [35] [36] used patient-derived data from the IRIS trial (using the EQ-5D instrument) for imatinib and IFNa and estimates from a clinical panel for HU treatment or assigned imatinib values to HU monotherapy, respectively. Ghatnekar et al. [37] was the only study that used utility data elicited with a TTO technique using the EQ-5D among lay persons.
Perspective
Nine models were conducted from the perspective of the healthcare system. Three models used a societal perspective and two models were conducted from a thirdparty payer perspective. The remaining models did not clearly state their perspective. The costs that are dependent on the perspective included in the analysis can have a high impact on the results (e.g., including indirect costs within a societal perspective vs. excluding them from a payer's perspective). However, even when the same perspective is chosen, the included costs can differ. For example, Ghatnekar et al. [37] (societal perspective) included the costs of increased public consumption as a result of survival gain, whereas Liberato et al. [17] (societal perspective) did not include them. Furthermore, when the annual income is included (e.g., Liberato et al. [17] ), comparisons between modeling studies in different countries become more complicated. Often a specific perspective is required from HTA agencies (e.g., National Institute for Health and Clinical Excellence requires the perspective of the national health system [45, 46] ) and certain costs should be included according to national guidelines. For example, the Swedish Council on Health Technology Assessment recommends: ''Having a societal perspective means that the costs and effects should be considered regardless of where and when they arise'' [47] .
Model Validation
Validation is a very valuable tool for judging a model's accuracy in predicting the outcomes of interest [48] . However, only a few studies validated the results in a comprehensive and formal way. As shown in Table 1 , most authors did not report a formal model validation, such as incorporating their set of parameters in other models, calculating the results and comparing the outcomes, or quantitatively comparing modeling results to data from clinical trials or epidemiologic studies. Most authors compared the results of their model to results of other studies, but did not go as far as to perform a cross-validation using their own input parameters in other published models [48] .
Personalized Medicine Aspects
In the emerging field of personalized medicine, it has become more important to consider patient-specific characteristics and individualized treatment strategies. None of the reviewed models evaluated comprehensive personalized medicine strategies, such as considering individual characteristics of patients (e.g. risk factors, biomarkers), to evaluate different treatment approaches.
Discussion
We included 18 models in our systematic review of CML treatment strategies. The studies addressed different target groups and settings and employed different modeling approaches.
The included modeling studies were published between 1996 and 2012. To our knowledge, no comparable comprehensive review has been published to date. Our inclusion criteria were intentionally broad so the review could capture a variety of model types, such as AUC/survival partitioned models, Markov cohort models, state-transition microsimulations, and DES. Furthermore, the review was not limited to specific treatment modalities, but allowed inclusion of all treatment approaches used to combat CML within the last decades. We specifically focused on the methodological aspects of the modeling approach and systematic framework, as opposed to study results.
Conceptualizing a model according to current clinical practice guidelines and taking into account all possible events and consequences, such as the potential for treatment failure at multiple time points, would make the model unduly complex [38] . In a Markov cohort model, the transition probabilities do not depend on past history. All events, consequences, and specific characteristics are modeled as different health states. As a consequence, the number of states would become unmanageable (''state explosion'') and patient-level microsimulation techniques for analysis would be necessary [38] . In microsimulation models, the number of different health states needed is smaller, as the history of individual patients can be stored and the information used for further decision making [38] . While models should remain transparent and intuitively understandable, they should also be complex enough to answer the question at a detailed level and, moreover, maintain face validity to clinical experts [49] . All of the models in this review simplified the nature of the disease in some manner.
The advent of new biomarkers, diagnostics, and resistance testing technologies may allow for the application of personalized treatment algorithms. These algorithms will capture a broad range of different treatment strategies with different dosing options and sequential application of the therapeutic agents. To incorporate different patient characteristics, tailored treatment approaches, and monitoring strategies, modeling will move towards more complex approaches, such as microsimulation. In these patient-level microsimulation models, the history of individual patients can be tracked [38] and used for future decision making, such as performing another test or the selection of the appropriate treatment strategy. In this review, we could only identify a sole report by Skrepnek and Ballard [26] applying microsimulation; however, advanced techniques to track and to incorporate individual patient histories were not used [26] .
Limitations
Some limitations of our review include the following. Articles that were not published in English or German were not included in this review. Our literature search was restricted to published full-text articles in certain databases. Therefore, some publications of decision-analytic models that met our inclusion criteria but were published in different databases, different languages, or only as abstracts might have been missed. Furthermore, it was beyond the scope of our review to perform a critical appraisal of the quality of the models or to evaluate the results of the studies. Thus, our review is not judging the reliability and validity of the results. In addition, the results of the review depict a subjective interpretation of the authors. The journals' limited space may have restricted the complete description of the models and led to misinterpretation from our side.
However, our systematic review provides a comprehensive appraisal of the methodological approaches employed in decision-analytic CML models. Our results can aid clinicians, health policy makers, and researchers with medical decision making and healthcare resource allocation by considering and weighing existing evidence and improving trial planning in the future.
Outlook and Recommendations
As the available CML data evolve, future models are likely to incorporate more personalized approaches, such as genetic testing, response levels (e.g., molecular, cytogenetic) for each treatment line, resistance testing, novel biomarkers, and personalized treatment algorithms. To incorporate these personalized treatment algorithms, modeling approaches will likely use more patient-level microsimulation techniques. AUC/SPM will no longer be sufficiently detailed to cover individualized diagnostictherapy algorithms. Furthermore, we recommend the separation of the single phases of the disease (CP, AP, BC) to allow for different survival probabilities, utilities, and costs associated with these disease stages.
A lifelong time horizon is the most appropriate for modeling outcomes of oncology therapies because it captures relevant aspects such as QALYs gained from prevented or delayed death [38] . In addition, one of the main reasons for developing decision-analytic models is to extrapolate results of short-term trials to estimate long-term survival and prognosis [5] . As most CML patients diagnosed in CP will still be alive and even be taking first-line treatment, 2-and 5-year time horizons might not be sufficient to capture the relevant aspects.
When considering QoL, one of the ways bias can be introduced to a model is if the utilities for the model's treatment options have been populated with data derived from different sources. This can happen when data are gathered from different patient populations. Bias is also possible if different QoL measurement instruments are used to elicit utility data. For example, Breitscheidel [23] used utility data derived from different sources: patient estimates were obtained using the EQ-5D questionnaire and estimates from a clinical panel were obtained using a standard gamble instrument. To avoid this problem nonaggregated outcome measures, such as life-years gained should be reported and compared.
In accordance with the ISPOR-SMDM Modeling Good Research Practices Task Force, a report on the validation is recommended to be included in every modeling study. The ''process for conducting validations and the level of validation'' of the model should be described. Such a report is necessary to build trust and gain confidence into the results of modeling studies by clinicians, health policy makers, and researchers [48] .
Currently, both ELN and NCCN (National Comprehensive Cancer Network) guidelines allow physicians to make their own decision of front-line therapy between imatinib, dasatinib, and nilotinib (depending on patient characteristics, safety, and tolerability) [3, 39] . We acknowledge that (a) there is yet no evidence of an overall survival advantage for any of the agents compared with others; (b) while the second-generation TKIs demonstrate more short-term efficacy, imatinib has more long-term safety data, and (c) different physicians may have more experience with one agent than others. However, in the near future imatinib will become generic, and the benefit of cost-effectiveness analysis and decision-analytic modeling will be very important in deciding how generic imatinib and second-line TKIs should be used. Pavey et al. [36] performed extensive sensitivity analyses on reduced prices for generic imatinib and found increasing ICERs for nilotinib compared with imatinib, and dasatinib ''becomes even worse value for money compared with imatinib''. However, there are still remaining questions, such as whether patients should be treated with a more potent second-generation TKI at first (''induction''), then switched to a cheaper generic imatinib (''maintenance'') if the patient shows a deep molecular response. Alternatively, should one start with generic imatinib, and switch to a second-line TKI only if the patient does not hit aggressive treatment milestones? Answering these questions with rigorous models may be the key to optimizing patient outcomes and managing health budgets.
An important area that will get more and more attention in the future is the different reimbursement schemes of new technologies and where uncertainty needs to be taken into account. Decisions on coverage have to be made regardless of remaining uncertainty. The concept of 'coverage with evidence development' (CED) is one approach to solve this problem. CED occurs when payers decide to pay for or reimburse a technology contingent on collection of additional evidence. In theory, the additional evidence will reduce uncertainty surrounding the decision over time [50] .
Conclusions
While several well-designed models for CML treatment strategies exist, we recommend future models assess the long-term efficacy and cost effectiveness of novel treatment options such as second-generation TKIs, including subgroup evaluations to allow for a more personalized decision making, and undertake model validation using independent data. Already available models with a short time horizon could be updated with more recent survival data.
